Treatment of active corticosteroid-resistant Graves' orbitopathy

Ophthalmic Plastic and Reconstructive Surgery

Volumn 30, Issue 2, 2014, Pages 162-167

  Pérez Moreiras, Jose Vicente ^a   Álvarez López, Alejandro ^a,b   Gómez, Estanislao Cardiel ^c  

^a International Institute of Orbit and Oculoplastics   (Spain)

^b Orbit Unit Clínica Piñero   (Spain)

^c HOSPITAL ROYO VILLANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; ETANERCEPT; GLUCOSE; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR; METHYLPREDNISOLONE; RITUXIMAB; THYROID STIMULATING IMMUNOGLOBULIN; TOCILIZUMAB;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHEMOSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ACTIVITY SCORE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIGESTIVE SYSTEM FUNCTION DISORDER; DIPLOPIA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG PULSE THERAPY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOMETER; EXOPHTHALMOS; EYE MOVEMENT; EYE SWELLING; EYELID RETRACTION; FATIGUE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; NEUTROPHIL COUNT; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RELAPSE; SCORING SYSTEM; SIDE EFFECT; STEROID THERAPY; TINNITUS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY; VISUAL FIELD;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; INTERVENTION STUDIES; MALE; MIDDLE AGED; ORBITAL DISEASES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84896389306     PISSN: 07409303     EISSN: 15372677     Source Type: Journal    
DOI: 10.1097/IOP.0000000000000037     Document Type: Article

References (27)

1. Smith TJ, Tsai CC, Shih MJ, et al. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 2008;18:983-8.
2. Douglas RS, Gianoukakis AG, Goldberg RA, et al. Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes. Clin Exp Immunol 2007;148:64-71.
3. Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 2000;85:776-80.
4. Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 2008;181:5768-74.
5. Bartalena L, Lai A, Compri E, et al. Novel immunomodulating agents for Graves orbitopathy. Ophthal Plast Reconstr Surg 2008;24:251-6.
6. Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005;90:5234-40.
7. Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:398-409.
8. Zoumalan CI, Cockerham KP, Turbin RE, et al. Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. J Neuroophthalmol 2007;27:205-14.
9. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726-38.
10. Silkiss RZ, Reier A, Coleman M, et al. Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 2010;26:310-4.
11. Hauser SL, Waubant E, Arnold DL, et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88.
12. El Fassi D, Hegedüs L, Nielsen CH. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;367:877; author reply 878.
13. Smith TJ. B cell depletion in Graves' disease: the right answer to the wrong question J Clin Endocrinol Metab 2007;92:1620-2.
14. Hasselbalch HC. B-cell depletion with rituximab- A targeted therapy for Graves' disease and autoimmune thyroiditis. Immunol Lett 2003;88:85-6.
15. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007;156:33-40.
16. Chong KL, Khanna D, Afifiyan NF, Hwang CJ, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroidassociated ophthalmopathy. Ophthalmology 2010;117:1-13.
17. Lehmann GM, Feldon SE, Smith TJ, et al. Immune mechanisms in thyroid eye disease. Thyroid 2008;18:959-65.
18. Jyonouchi SC, Valyasevi RW, Harteneck DA, et al. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy. Thyroid 2001;11:929-34.
19. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
20. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88.
21. Rose-John S, Waetzig GH, Scheller J, et al. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007;11:613-24.
22. Kaneko A. Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy. Ther Adv Chronic Dis 2013;4:15-21.
23. Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47:9-14.
24. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88.
25. Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, et al. CD8lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity. Endocr Res 2012;37:89-95.
26. Smith RS, Smith TJ, Blieden TM, et al. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997;151:317-22.
27. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003;24:802-35.